Udaya S Rangaswamy
Overview
Explore the profile of Udaya S Rangaswamy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Avanzino B, Prabhakar K, Dalvi P, Hartstein S, Kehm H, Balasubramani A, et al.
Oncoimmunology
. 2022 Aug;
11(1):2113697.
PMID: 36016696
The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the...
2.
Harris K, Lorentsen K, Malik-Chaudhry H, Loughlin K, Basappa H, Hartstein S, et al.
Sci Rep
. 2021 May;
11(1):10592.
PMID: 34011961
The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events...
3.
Malik-Chaudhry H, Prabhakar K, Ugamraj H, Boudreau A, Buelow B, Dang K, et al.
MAbs
. 2021 Apr;
13(1):1890411.
PMID: 33818299
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been...
4.
Xu Q, Rangaswamy U, Wang W, Robbins S, Harper J, Jin H, et al.
Int J Cancer
. 2019 Oct;
146(2):531-541.
PMID: 31584185
We have developed an oncolytic Newcastle disease virus (NDV) that has potent in vitro and in vivo anti-tumor activities and attenuated pathogenicity in chickens. In this ex vivo study using...
5.
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies
Trinklein N, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al.
MAbs
. 2019 Jan;
11(4):639-652.
PMID: 30698484
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. The use of novel anti-CD3 binding domains with more...
6.
Harris K, Force Aldred S, Davison L, Ogana H, Boudreau A, Bruggemann M, et al.
Front Immunol
. 2018 May;
9:889.
PMID: 29740455
We created a novel transgenic rat that expresses human antibodies comprising a diverse repertoire of heavy chains with a single common rearranged kappa light chain (IgKV3-15-JK1). This fixed light chain...
7.
Rangaswamy U, Wang W, Cheng X, McTamney P, Carroll D, Jin H
J Virol
. 2017 Jun;
91(16).
PMID: 28592535
Newcastle disease virus (NDV) is an oncolytic virus being developed for the treatment of cancer. Following infection of a human ovarian cancer cell line (OVCAR3) with a recombinant low-pathogenic NDV,...
8.
Rangaswamy U, Cotter C, Cheng X, Jin H, Chen Z
J Gen Virol
. 2016 May;
97(8):1765-1770.
PMID: 27153814
Newcastle disease virus (NDV) is being developed as an oncolytic virus for virotherapy. In this study we analysed the regulation of complement-mediated inactivation of a recombinant NDV in different host...
9.
Rangaswamy U, OFlaherty B, Speck S
PLoS One
. 2014 Aug;
9(8):e105197.
PMID: 25122496
A common strategy shared by all known gammaherpesviruses is their ability to establish a latent infection in lymphocytes--predominantly in B cells. In immunocompromised patients, such as transplant recipients or AIDS...
10.
Rangaswamy U, Speck S
PLoS Pathog
. 2014 Jan;
10(1):e1003858.
PMID: 24391506
Reactivation of the gammaherpesviruses Epstein-Barr virus (EBV), Kaposi's sarcoma-associated herpesvirus (KSHV) and murine gammaherpesvirus 68 (MHV68) from latently infected B cells has been linked to plasma cell differentiation. We have...